Santos da Silva Jorge 4
4 · MoonLake Immunotherapeutics · Filed Jul 13, 2026
Research Summary
AI-generated summary of this filing
MoonLake (MLTX) CEO Santos da Silva Jorge Sells 102,225 Shares
What Happened
Santos da Silva Jorge, Chief Executive Officer of MoonLake Immunotherapeutics (MLTX), sold a total of 102,225 shares in two open‑market transactions for gross proceeds of about $2,046,205. On 2026-07-09 he disposed of 33,936 shares at a weighted average price of $20.01 ($679,059 total). On 2026-07-10 he disposed of 68,289 shares at a weighted average price of $20.02 ($1,367,146 total). These were sales (not purchases) and therefore represent distributions of stock rather than an additional investment in the company.
Key Details
- Transaction dates and reported prices:
- 2026-07-09: 33,936 shares at $20.01 (weighted avg) — $679,059
- 2026-07-10: 68,289 shares at $20.02 (weighted avg) — $1,367,146
- Total shares sold: 102,225; total gross proceeds ≈ $2,046,205.
- Shares owned after transaction: Not disclosed in the provided filing excerpt.
- Footnotes:
- F1: Sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 31, 2026.
- F2/F3: Reported prices are weighted averages; individual trades ranged $20.00–$20.03 and $20.00–$20.10. Detailed per‑trade pricing can be provided to the SEC staff on request.
- Filing: Form 4 filed on 2026-07-13 (covers trades on July 9–10) — filing date appears to be within the typical two-business-day reporting window.
Context
A Rule 10b5-1 plan allows insiders to transact at pre-set times and is commonly used to avoid questions about trading on nonpublic information; it does not by itself indicate the insider’s current view of the company. Sales reduce insider stock holdings and generate cash for the insider; they are routine and not as informative as purchases when interpreting insider sentiment.
Insider Transaction Report
- Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F2]2026-07-09$20.01/sh−33,936$679,059→ 2,843,182 total - Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F3]2026-07-10$20.02/sh−68,289$1,367,146→ 2,774,893 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.